Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
Decorative Image of a building in Mainz, Germany

30 May Odylia CEO to speak at the International Symposium on Usher Syndrome

Posted at 14:29h in Press Releases by Odylia Media

Odylia will be attending the International Symposium on Usher Syndrome July 19-21 in Mainz, Germany. CEO, Scott Dorfman, will be speaking during the scientific presentations on July 20 to present Odylia’s mission to move science to the clinic. Odylia will also present a poster at the conference.

Visit Website

Print page


Latests Posts
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform

    13 May, 2025
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy

    05 May, 2025
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event

    10 April, 2025
Categories
  • Press Releases
  • Uncategorized
Tags
Amgen Prize Board of Directors Comend Concordia Summit February 2025 gene therapy Joy Cavagnaro marketplace MIT Solve nephrocystin-1 nephronophthisis NPHP1 NPHP1 Family Foundation Odylia patient groups PURA purine-rich element-binding protein alpha purine rich rare disease Rare Disease Day Senior-Loken Syndrome SKS Smith Kingsmore Smith Kingsmore Foundation The Collective The Odylia Collective
Services
  • Odylia Pipeline & Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs